SKYEPHARMA PLC - RESULT OF AGM

LONDON, UK, 22 May 2014 - Skyepharma PLC (LSE: SKP) announces the results of the voting by shareholders at the Annual General Meeting held earlier today.  All resolutions were passed with the requisite majorities on a show of hands.

In accordance with Listing Rule 9.6.2, a copy of the resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the National Storage Mechanism, and will be available for inspection at www.morningstar.co.uk/uk/NSM

The full text of all the resolutions passed at the meeting can be found in the Notice of Annual General Meeting, which is available for inspection at www.morningstar.co.uk/uk/NSMand on the Company's website at www.skyepharma.com.

Full details of the proxy voting will be available on our website (www.skyepharma.com) later today.

For further information please contact:

Skyepharma PLC

Peter Grant, Chief Executive Officer

+44 20 7881 0524


Andrew Derodra, Chief Financial Officer



John Murphy, Group Counsel and Company Secretary





Financial Dynamics

Julia Phillips

+44 20 3727 1000


Natalie Garland-Collins





About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products.  The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses.  The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies.  For more information, visit www.skyepharma.com


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRAGFMGZKZZMGDZM
distributed by